Cocrystal Pharma, Inc. reported a net loss of $8.8 million for the fiscal year ending December 31, 2025, a significant reduction from the $17.5 million loss recorded in the previous year. The company's total operating expenses decreased to $9 million from $17.9 million, primarily due to reduced research and development costs, which fell from $12.5 million in 2024 to $5.1 million in 2025. This decline was attributed to the winding down of clinical study costs, particularly related to the CC-42344 influenza product candidate, and a reduction in employee-related expenses.
The company has made strategic advancements in its product pipeline, focusing on antiviral therapeutics for influenza, norovirus, and coronaviruses. Notably, Cocrystal received authorization from the UK Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge study for CC-42344, although the initial study faced challenges due to low infection rates among participants. Additionally, the company is developing CDI-988, a novel protease inhibitor for norovirus and coronaviruses, which has shown favorable safety and tolerability in early clinical trials.
Cocrystal's operational metrics indicate a lean workforce, with only 10 full-time employees as of December 31, 2025, down from previous years. The company has also engaged in various financing activities, raising approximately $5.4 million through equity sales in 2025, which included a registered direct offering and a concurrent private placement of common stock and warrants. However, the company has expressed concerns regarding its liquidity, stating that its current cash reserves may not be sufficient to fund operations for the next 12 months, necessitating further capital raises.
Looking ahead, Cocrystal plans to continue its research and development efforts, particularly for CC-42344 and CDI-988, while navigating the complexities of clinical trials and regulatory approvals. The company acknowledges the need for additional funding to support its ongoing projects and has indicated that achieving profitability will depend on the successful development and commercialization of its product candidates. The management remains cautious about the future, given the uncertainties surrounding market conditions and the competitive landscape in the biotechnology sector.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral therapeutics targeting RNA viruses such as influenza, coronaviruses, norovirus, and hepatitis C. Utilizing proprietary structure-based drug design, it aims to create safe, effective, broad-spectrum, and resistance-high barrier antiviral drugs. Its core activities include preclinical and clinical research, with a focus on unmet medical needs in infectious diseases. The company relies on collaborations, third-party manufacturing, and advanced scientific platforms to develop innovative antiviral treatments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.